A detailed history of Capital Insight Partners, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Capital Insight Partners, LLC holds 1,424 shares of LLY stock, worth $1.07 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
1,424
Previous 1,514 5.94%
Holding current value
$1.07 Million
Previous $1.37 Million 7.96%
% of portfolio
0.22%
Previous 0.26%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

SELL
$772.14 - $960.02 $69,492 - $86,401
-90 Reduced 5.94%
1,424 $1.26 Million
Q2 2024

Jul 24, 2024

SELL
$724.87 - $909.04 $54,365 - $68,178
-75 Reduced 4.72%
1,514 $1.37 Million
Q1 2024

Apr 16, 2024

SELL
$592.2 - $792.28 $153,379 - $205,200
-259 Reduced 14.02%
1,589 $1.24 Million
Q4 2023

Jan 24, 2024

SELL
$525.19 - $619.13 $165,434 - $195,025
-315 Reduced 14.56%
1,848 $1.08 Million
Q3 2023

Oct 30, 2023

SELL
$434.7 - $599.3 $54,337 - $74,912
-125 Reduced 5.46%
2,163 $1.16 Million
Q2 2023

Jul 21, 2023

SELL
$350.74 - $468.98 $220,264 - $294,519
-628 Reduced 21.54%
2,288 $1.07 Million
Q1 2023

Apr 27, 2023

BUY
$310.63 - $364.82 $246,950 - $290,031
795 Added 37.48%
2,916 $1 Million
Q4 2022

Feb 07, 2023

SELL
$321.55 - $374.67 $45,017 - $52,453
-140 Reduced 6.19%
2,121 $775,000
Q3 2022

Oct 20, 2022

SELL
$296.48 - $337.87 $44,472 - $50,680
-150 Reduced 6.22%
2,261 $731,000
Q4 2021

Jan 20, 2022

SELL
$224.85 - $279.04 $42,721 - $53,017
-190 Reduced 7.3%
2,411 $666,000
Q3 2021

Oct 13, 2021

SELL
$221.6 - $272.71 $42,104 - $51,814
-190 Reduced 6.81%
2,601 $601,000
Q2 2021

Aug 02, 2021

SELL
$180.55 - $233.54 $56,331 - $72,864
-312 Reduced 10.05%
2,791 $641,000
Q1 2021

Apr 20, 2021

BUY
$164.32 - $212.72 $509,884 - $660,070
3,103 New
3,103 $580,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $713B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Capital Insight Partners, LLC Portfolio

Follow Capital Insight Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Insight Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Insight Partners, LLC with notifications on news.